fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Metabolic hormone ‘leptin’ linked to poor vaccine response

Written by | 15 Jun 2021

Reduced levels of a metabolic hormone known as leptin is linked to poor vaccine antibody responses in the general population, a University of Queensland study has found. The… read more.

Testing and using drug treatment during a pandemic

Written by | 10 Jun 2021

Interview and article by Christine Clark. Steve Kirsch, CEO of the Covid-19 Early Treatment Fund (CETF) explains how a study in Nepal will advance our understanding of effective… read more.

Treatment of covid-19 with ivermectin + fluvoxamine combination

Written by | 9 Jun 2021

Interview and article by Christine Clark. A combination of fluvoxamine and ivermectin for early treatment of covid-19 is highly effective and should be implemented widely, according to Steve… read more.

Fluvoxamine for early treatment of covid-19

Written by | 8 Jun 2021

Article by Christine Clark. Evidence from trials and real world experience shows that selective serotonin reuptake inhibitors (SSRIs) are effective in treating acute covid and preventing long-haul covid.

Trials of fluvoxamine for covid-19

Written by | 8 Jun 2021

Interview and article by Christine Clark. Early treatment of covid-19 with fluvoxamine has been remarkably effective in two trials, one of which was funded by the Covid-19 Early… read more.

Mild COVID-19 induces lasting antibody protection, study finds

Written by | 4 Jun 2021

People who have had mild illness develop antibody-producing cells that can last lifetime Washington University School of Medicine Months after recovering from mild cases of COVID-19, people still… read more.

MHRA approves Ad26.COV2-S [recombinant] for active immunisation against COVID-19 within the United Kingdom – Janssen

Written by | 30 May 2021

Ad26.COV2-S [recombinant] a single-dose coronavirus vaccine from Janssen, part of Johnson & Johnson, has been approved by the MHRA (UK) and is indicated for active immunisation to prevent… read more.

Four-month TB therapy proves as effective as 6-month standard regimen

Written by | 24 May 2021

Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time… read more.

Prophylaxis with ivermectin and the next steps

Written by | 22 May 2021

Interview and article by Christine Clark. Ivermectin should be used for prophylaxis and treatment of covid-19 throughout India, according to Dr Suryakant (Head of the Department of Respiratory… read more.

AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan

Written by | 22 May 2021

AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and… read more.

Home isolation and ivermectin-based treatment kits

Written by | 21 May 2021

Interview and article by Christine Clark. Dr Suryakant (Head of the Department of Respiratory Medicine at King George Medical University in Lucknow, India) explains how an ivermectin-based therapy… read more.

The story behind ivermectin use in India

Written by | 20 May 2021

Interview and article by Christine Clark. Dr Suryakant explains how a white paper enabled him and his colleagues to argue the case for ivermectin use and resulted in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.